| Literature DB >> 28978315 |
Qin Jiang1, Manyi Yang2, Zhan Qu3, Jixiang Zhou3, Qi Zhang4.
Abstract
BACKGROUND: The aim of this in vitro study was to measure the enhanced anticancer effects of Res (resveratrol) on PA (paclitaxel) in HepG2 human liver cancer cells.Entities:
Keywords: Apoptosis; HepG2 human liver cancer cells; Paclitaxel; Resveratrol; Sensitizing
Mesh:
Substances:
Year: 2017 PMID: 28978315 PMCID: PMC5628430 DOI: 10.1186/s12906-017-1956-0
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Sequences of primers were used in this study
| Gene name | Sequence |
|---|---|
| Caspase-3 | Forward: 5′-CAA ACT TTT TCA GAG GGG ATC G-3′ |
| Reverse: 5′-GCA TAC TGT TTC AGC ATG GCA-3′ | |
| Caspase-8 | Forward: 5′-CCC CAC CCT CAC TTT GCT-3′ |
| Reverse: 5′-GGA GGA CCA GGC TCA CTT A-3′ | |
| Caspase-9 | Forward: 5′-GGC CCT TCC TCG CTT CAT CTC-3′ |
| Reverse: 5′-GGT CCT TGG GCC TTC CTG GTA T-3′ | |
| Bax | Forward: 5′-AAG CTG AGC GAG TGT CTC CGG CG-3′ |
| Reverse: 5′-CAG ATG CCG GTT CAG GTA CTC AGT C-3′ | |
| Bcl-2 | Forward: 5′-CTC GTC GCT ACC GTC GTG ACT TGG-3′ |
| Reverse: 5′-CAG ATG CCG GTT CAG GTA CTC AGT C-3′ | |
| Bcl-xL | Forward: 5′-CCC AGA AAG GAT ACA GCT GG-3′ |
| Reverse: 5′-GCG ATC CGA CTC ACC AAT AC-3′ | |
| p53 | Forward: 5′-GCT CTG ACT GTA CCA CCA TCC-3′ |
| Reverse: 5′-CTC TCG GAA CAT CTC GAA GCG-3′ | |
| p21 | Forward: 5′-CTC AGA GGA GGC GCC ATG-3′ |
| Reverse: 5′-GGG CGG ATT AGG GCT TCC-3′ | |
| NF-κB | Forward: 5′-CAC TTA TGG ACA ACT ATG AGG TCT CTG G-3′ |
| Reverse: 5′-CTG TCT TGT GGA CAA CGC AGT GGA ATT TTA GG-3′ | |
| IκB-α | Forward: 5′-GCT GAA GAA GGA GCG GCT ACT-3′ |
| Reverse: 5′-TCG TAC TCC TCG TCT TTC ATG GA-3′ | |
| Fas | Forward: 5′-GAA ATG AAA TCC AAA GCT-3′ |
| Reverse: 5′-TAA TTT AGA GGC AAA GTG GC-3′ | |
| FasL | Forward: 5′-GGA TTG GGC CTG GGG ATG TTT CA-3′ |
| Reverse: 5′-TTG TGG CTC AGG GGC AGG TTG TTG-3′ | |
| TIMP-1 | Forward: 5′-GTC AGT GAG AAG CAA GTC GA-3′ |
| Reverse: 5′-ATG TTC TTC TCT GTG ACC CA-3′ | |
| TIMP-2 | Forward: 5′-TGG GGA CAC CAG AAG TCA AC-3′ |
| Reverse: 5′-TTT TCA GAG CCT TGG AGG AG-3′ | |
| MMP-2 | Reverse: 5′-CTT CTT CAA GGA CCG GTT CA-3′ |
| Forward: 5′-GCT GGC TGA GTA CCA GTA-3′ | |
| MMP-9 | Reverse: 5′-TGG GCT ACG TGA CCT ATG AC-3′ |
| Forward: 5′-GCC CAG CCC ACC TCC ACT CC-3′ | |
| HIAP-1 | Reverse: 5′-GCC TGA TGC TGG ATA ACT GG-3′ |
| Forward: 5′-GGC GAC AGA AAA GTC AAT GG-3′ | |
| HIAP-2 | Reverse: 5′-GCC TGA TGC TGG ATA ACT GG-3′ |
| Forward: 5′-GCT CTT GCC AAT TCT GAT GG-3′ | |
| COX-2 | Reverse: 5′-TTA AAA TGA GAT TGT CCG AA-3′ |
| Forward: 5′-AGA TCA CCT CTG CCT GAG TA-3′ | |
| iNOS | Reverse: 5′-AGA GAG ATC GGG TTC ACA-3′ |
| Forward: 5′-CAC AGA ACT GAG GGT ACA-3′ | |
| EGF | Reverse: 5′-GCC AAG CTC AGA AGG CTA C-3′ |
| Forward: 5′-CAG GCC AGC CTC GTC TCA T-3′ | |
| EGFR | Reverse: 5′-TCG GTG CTG TGC GAT TTA-3′ |
| Forward: 5′-TTT CTG GCA GTT GCT CCT C-3′ | |
| VEGF | Reverse: 5′-GCA CCC ATG GCA GAA GGA GGA G-3′ |
| Forward: 5′-GTG CTG ACG CTA ACT GAC C-3′ | |
| Fit-1 | Reverse: 5′-CAA GTG GCCAGA GGC ATG GAG TT-3′ |
| Forward: 5′-GAT GTA GTC TTTACC ATC CTG TTG-3′ | |
| GAPDH | Reverse: 5′-CGG AGT CAA CGG ATT TGG TC-3′ |
| Forward: 5′-AGC CTT CTC CAT GGT CGT GA-3′ |
Fig. 1Effect of resveratrol (a) and paclitaxel (b) on the growth of human normal liver cell lines L02. a Mean values with different letters over the points are no significantly different (P < 0.05) according to Dunnett’s post-hoc test
Fig. 2Effect of resveratrol (a) and paclitaxel (b) on the growth of HepG2 human liver cancer cells. a-g Mean values with different letters over the points are significantly different (P < 0.05) according to Dunnett’s post-hoc test
Growth inhibitory effects of HepG2 human liver cancer cells by resveratrol and paclitaxel by an MTT
| Treatment | OD570 value | Inhibitory rate (%) |
|---|---|---|
| Control | 0.431 ± 0.003a | / |
| PA-L | 0.322 ± 0.006b | 25.3 ± 2.1d |
| Res + PA-L | 0.287 ± 0.008c | 33.4 ± 2.2c |
| PA-H | 0.202 ± 0.008d | 53.1 ± 2.3b |
| Res + PA-H | 0.089 ± 0.005e | 79.4 ± 1.9a |
PA-L 5 μg/mL of paclitaxel, Res + PA-L 10 μg/mL of resveratrol +5 μg/mL of paclitaxel, PA-H 10 μg/mL of paclitaxel, Res + PA-H 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
a-eMean values with different letters in the same column are significantly different (P < 0.05) according to Dunnett’s post-hoc test
Fig. 3Apoptosis inducing effects (DNA content of sub-G1) of resveratrol (Res) and paclitaxel (PA) in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 4The mRNA and protein expression of caspase-3 caspase-8 and caspase-9 in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 5The mRNA and protein expression of Bax, Bcl-2 and Bcl-xL in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 6The mRNA and protein expression of Fas and FasL in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 7The mRNA and protein expression of p53 and p21 in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 8The mRNA and protein expression of HIAP-1 and HIAP-2 in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 9The mRNA and protein expression of NF-κB and IκB-α in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 10The mRNA and protein expression of COX-2 and iNOS in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 11The mRNA and protein expression of TIMP-1, TIMP-2, MMP-2 and MMP-9 in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel
Fig. 12The mRNA and protein expression of EGF, EGFR, VEGF and Fit-1 in HepG2 human liver cancer cells. a-e Mean values with different letters over the bars are significantly different (P < 0.05) according to Dunnett’s post-hoc test. PA-L: 5 μg/mL of paclitaxel; Res + PA-L: 10 μg/mL of resveratrol +5 μg/mL of paclitaxel; PA-H: 10 μg/mL of paclitaxel; Res + PA-H: 10 μg/mL of resveratrol +10 μg/mL of paclitaxel